Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$21.89 -10.03%

-$3.24 today

Market cap
$3.71B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 2.75M

Average 3.67M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$138.89M

FY 2025 · Annual

Investing Cash Flow

-$40.87M

FY 2025 · Annual

Financing Cash Flow

$222.50M

FY 2025 · Annual

+366.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.24M)(108.18M)(101.74M)(130.3M)(101.59M)
Depreciation & Amortization897K1.61M2.42M2.5M2.28M
Deferred Income Tax00000
Stock-Based Compensation7.83M14.23M19.08M28.9M26.43M
Change in Working Capital(11.35M)(18.49M)(37.97M)(31.75M)(67.2M)
Accounts Receivables002M00
Inventory00000
Accounts Payables1.23M1.1M(1.71M)(1.18M)(825K)
Other Working Capital(12.58M)(19.59M)(38.26M)(30.56M)(66.37M)
Other Non-Cash Items1.32M1.75M234K(849K)1.2M
Operating Cash Flow(59.53M)(109.08M)(117.98M)(131.5M)(138.89M)
Capital Expenditures(1.84M)(7.69M)(1.53M)(754K)(1.05M)
Acquisitions (Net)00000
Purchases of Investments(372.36M)(208.5M)(310.57M)(240.89M)(264.46M)
Sales of Investments190.76M242.6M353.53M327.77M224.64M
Other Investing Activities00000
Investing Cash Flow(183.43M)26.4M41.43M86.13M(40.87M)
Debt Repayment342.11M0000
Common Stock Issued0080.02M41.72M222.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(14.78M)1.62M2.39M5.94M(36K)
Financing Cash Flow357.33M1.62M82.41M47.66M222.5M
Effect of Forex Changes00000
Net Change in Cash114.36M(81.07M)5.85M2.29M42.75M
Free Cash Flow(61.36M)(116.77M)(119.51M)(132.26M)(139.93M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$101.6M
+ D&A$2.3M
+ Stock-Based Comp$26.4M
+ Deferred Tax$0
- Working Capital-$67.2M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$138.9M
- Capex-$1.0M
= Free Cash Flow-$139.9M

Analysis

FY2025 free cash flow is -$139.9M. FCF conversion is 137.7% of net income. Operating cash flow was -$138.9M, with capex of -$1.0M. The largest bridge item is Working Capital at -$67.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
4Statement of changes in beneficial ownershipNov 4, 2026

Does TNGX generate free cash flow?

Tango Therapeutics, Inc. (TNGX) generated -$139.93M of free cash flow in fiscal 2025.

How much operating cash flow does TNGX produce?

Operating cash flow was -$138.89M, before capital expenditures of $1.05M.